首页> 外国专利> USE OF ERBB3 INHIBITORS IN THE TREATMENT OF TRIPLE NEGATIVE AND BASAL-LIKE BREAST CANCERS

USE OF ERBB3 INHIBITORS IN THE TREATMENT OF TRIPLE NEGATIVE AND BASAL-LIKE BREAST CANCERS

机译:ERBB3抑制剂在三阴性和基础性乳腺癌治疗中的应用

摘要

Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor.
机译:提供了通过使肿瘤细胞与ErbB3抑制剂例如抗ErbB3抗体接触来抑制三阴性乳腺肿瘤和基底样乳腺肿瘤生长的方法。还提供了通过向患者施用ErbB3抑制剂例如抗ErbB3抗体来治疗患者的三阴性乳腺癌或基底样乳腺癌的方法。治疗方法可以进一步包括选择患有三阴性乳腺癌或基底样乳腺癌的患者,然后向该患者施用ErbB3抑制剂。治疗方法还可以进一步包括与ErbB3抑制剂联合给予患者至少一种另外的抗癌剂。

著录项

  • 公开/公告号US2019119401A1

    专利类型

  • 公开/公告日2019-04-25

    原文格式PDF

  • 申请/专利权人 MERRIMACK PHARMACEUTICALS INC.;

    申请/专利号US201815994393

  • 发明设计人 VICTOR MOYO;GABRIELA GARCIA;

    申请日2018-05-31

  • 分类号C07K16/32;A61K31/517;A61K39/395;A61K45/06;A61K31/337;C07K16/40;C07K16/28;C07K16/30;C07K16/22;

  • 国家 US

  • 入库时间 2022-08-21 12:07:58

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号